Gene Solutions presents real-world data from 225,092 Asian pregnant women at ISPD 2026

Here is the rewritten news content as clean, well-structured English Markdown.

Publication date: 2026-07-22 04:00:17

Gene Solutions Showcases Global Evidence and Responsible Innovation in Prenatal and Women's Genomic Health at ISPD 2026

Published - July 22, 2026 09:30 am IST

SINGAPORE, July 22, 2026 /PRNewswire/ -- Gene Solutions, a global biotechnology company focused on accessible and responsible genomics, participated as a Premier Partner at the 30th International Conference on Prenatal Diagnosis and Therapy (ISPD 2026), held virtually from July 7–9.

As a Premier Partner, Gene Solutions presented Asia-led real-world evidence from large-scale NIPT-integrated carrier screening, alongside advances in AI-enabled pregnancy-risk assessment and minimally invasive molecular approaches to women's health.

Across an industry symposium, a scientific session, two oral presentations and three scientific posters, the company presented data and expert perspectives on how genomics, epigenomics and artificial intelligence may support more comprehensive, personalized and minimally invasive care throughout pregnancy and across women's health.

ISPD 2026 convened specialists in prenatal diagnosis, fetal medicine, obstetrics, gynecology and genetic counselling to advance care for women, children and families worldwide. Gene Solutions brought together experts from Asia, Australia, Europe and the United States to examine both the opportunities and responsibilities associated with the expansion of genomic and epigenomic medicine.

Real-World Evidence and Integrated Prenatal Screening

Gene Solutions' industry symposium, "Advancing Prenatal Screening: Validation and Clinical Utility of Integrated Non-Invasive Testing with Focus on Carrier Screening and Single-Gene Disorders," explored how routine non-invasive prenatal testing (NIPT) could evolve beyond chromosomal aneuploidy screening. The session was moderated by Ida Deleskog Lindstroem, Global Medical Affairs Director at Gene Solutions.

Key Insights from the Symposium

• Dr. Natalie Chandler of the NHS North Thames Genomic Laboratory Hub and NHS Great Ormond Street Hospital for Children (UK) shared insights from the UK's experience moving from trisomy screening toward broader prenatal genomics, including NIPT for monogenic disorders. She emphasized that broader testing must be accompanied by rigorous patient selection, robust variant interpretation, laboratory quality assurance and access to genetics-informed counselling. Dr. Chandler also highlighted important challenges, including maternal somatic mosaicism, inconsistent variant classification, variable penetrance and differences among available panels.

• Dr. Sang Hung Tang, Medical Director of the Medical Genetics Institute of Ho Chi Minh City (Vietnam), presented large-scale real-world evidence from 225,092 Asian pregnant women screened for 18 common recessive conditions through routine NIPT infrastructure across Vietnam, the Philippines, Indonesia, Malaysia, Taiwan region and India between February 2025 and February 2026. The study found that more than one in four pregnant women carried at least one screened recessive condition, with prominent examples including alpha-thalassemia, cystic fibrosis, beta-thalassemia, 5α-reductase deficiency and G6PD deficiency, an X-linked condition.

Through triSure Procare, Gene Solutions has integrated maternal carrier screening and screening for selected dominant single-gene disorders into a routine NIPT offering, supporting a broader view of reproductive genetic risk from a single maternal blood draw. The data illustrate the potential to leverage existing NIPT workflows for expanded carrier screening from a single maternal blood sample, while underscoring the importance of partner testing, confirmatory diagnostics and expert genetic counselling.

AI-Driven Multi-Omic Biomarkers

Dr. Hoa Giang, Co-founder and Chief Data Science Officer at Gene Solutions (US), and Dr. Minh-Duy Phan, Head of Data Science at Gene Solutions (Australia), presented emerging research on AI-driven multi-omic biomarkers for the earlier prediction of gestational diabetes mellitus and preterm birth. Their work analyzes fragmentomic and other molecular signals already present in cell-free DNA data, creating a potential...